About
Tim Haines has over 40 years of international management experience in life sciences across public and private companies. He joined Abingworth in 2005 as a Partner and later served as Chairman and Managing Partner; before that he was the founding CEO of Abingworth portfolio company Astex Therapeutics, which was acquired by Otsuka Pharmaceuticals. Earlier roles include CEO of two divisions of Datascope Corp, CEO of Thackray Inc, and General Manager of Baxter UK. He holds a BSc from Exeter University and an MBA from INSEAD.
Contact· self-published, not guessed
Invests in
Biotech
Experience
- TenUChaircurrent2024 — presentGreater London
- IMU BiosciencesNon Executive Chaircurrent2024 — presentLondon, England, United Kingdom
- AbingworthManaging Director and Executive Partnercurrent2023 — presentLondon, England, United Kingdom
- AbingworthManaging Partner: Abingworth became part of Carlyle (NASDAQ: CG) on 1 August 2022.2022 — 2023London, England, United Kingdom
- AbingworthChairman and Managing Partner2019 — 2022London, United Kingdom
- AbingworthManaging Partner2015 — 2019London, United Kingdom
- AbingworthPartner2005 — 2015London, United Kingdom
- Oxford University InnovationAdvisory Board Membercurrent2022 — present
- Wellcome TrustPanel Member - Health Innovation Challenge Fund2009 — 2014
- Astex PharmaceuticalsCEO2000 — 2005Greater Cambridge Area
- DatascopeCEO Intervascular Inc. and Patient Monitoring1993 — 2000France / USA
- Telectronics Pacing Systems, Inc.General Manager / VP R and D and Manufacturing1990 — 1993Paris / US
- Thackary Orthopedic Inc.CEO1987 — 1990USA
- Baxter International Inc.General Manager1983 — 1987UK
Skills & more
Strategy1Private Equity3Venture Financing2Angel InvestingPrivate PlacementsLBO1IPO1M&A experienceGrowth Capital4Mergers & Acquisitions3Business Development8Biotechnology10
+8 more
Venture CapitalManufacturingMedical DevicesCorporate DevelopmentCapital RaisingEntrepreneurshipBusiness StrategyStart-upsLanguages French
From Tim's professional profile.
Investments
Board seats
Adaptate BiotherapeuticsAntaresAstexFoveaGammaDelta TherapeuticsHBIMEDIAN TechnologiesPowderMedScorpionSientraStanmoreVenatorx
Per the firm's website.
Colleagues at Abingworth
Alex Asquith
Counsel at Abingworth
Amit Khasgiwala
Investment Professional at Innovatus Capital Partners
Andrew Sinclair
Managing Director, Head of Publics & Late Stage at Abingworth
Ankur Shah
Vice President, CCD at Abingworth
Anna Slezak
Senior Associate at Abingworth
Bali Muralidhar
Global Head of Life Sciences & CIO at Abingworth
Carlos Paya
Venture Partner at Ysios Capital
Dayle Hogg
Operating Executive at Abingworth
Frequently asked questions
- Who is Tim Haines?
- Tim Haines has over 40 years of international management experience in life sciences across public and private companies. He joined Abingworth in 2005 as a Partner and later served as Chairman and Managing Partner; before that he was the founding CEO of Abingworth portfolio company Astex Therapeutics, which was acquired by Otsuka Pharmaceuticals. Earlier roles include CEO of two divisions of Datascope Corp, CEO of Thackray Inc, and General Manager of Baxter UK. He holds a BSc from Exeter University and an MBA from INSEAD.
- Where does Tim Haines work?
- Tim Haines is Managing Partner at Abingworth.
- What does Tim Haines invest in?
- Tim Haines invests in Biotech.
- What check size does Tim Haines write?
- Tim Haines typically writes checks of $15M – $30M.
- What boards does Tim Haines sit on?
- Tim Haines holds tracked board seats at Adaptate Biotherapeutics, Antares, Astex, Fovea, GammaDelta Therapeutics, HBI, MEDIAN Technologies, PowderMed, Scorpion, Sientra.
- Where did Tim Haines go to school?
- Tim Haines studied at INSEAD (Master of Business Administration (MBA), Business Administration and Management); Harvard Business School (Strategic Marketing Course); University of Exeter (BSc Hons).
Same school
Also attended INSEAD804
Alexandre ProtCo-founder & CEO of QontoSteve AnaviCo-founder & President of QontoPatrick ClaessenPartner at Cottonwood Technology FundChris BischoffInvestment Team at General CatalystJan HammerInvestor at Index VenturesSandra SchwarzerInvestor at Index Ventures
.jpg)
+ 798 more
Also attended Harvard Business School2,000
Brad GerstnerFounder & CEO of Altimeter CapitalAileen LeeFounder & Managing Partner of Cowboy VenturesTim DraperFounder of Draper AssociatesMamoon HamidPartner at Kleiner PerkinsNeeraj AgrawalGeneral Partner at Battery VenturesHristo BorisovCo-founder & CEO of Payhawk
+ 1,994 more
Also attended University of Exeter109
Tom McGinnGeneral Counsel at NorthzoneAlexandra FarmerFund Accountant at NorthzoneElsa Backdahl NordenfalkSenior Director of Capital Formation at Pantera CapitalGiles Johnstone-ScottInvestor at MedicxiHector MasonGeneral Partner at Episode1Stephen ChandlerManaging Partner at Notion Capital
%20(1).avif)
+ 103 more
Shared employers
Also worked at IMU Biosciences4
Also worked at Abingworth18
Carlos PayaVenture Partner at Ysios CapitalSarah ShackeltonAdvisor at Delin VenturesBali MuralidharGlobal Head of Life Sciences & CIO at AbingworthKurt von EmsterManaging Partner at AbingworthJayson PunwaniManaging Director, Head of Venture at AbingworthAndrew SinclairManaging Director, Head of Publics & Late Stage at Abingworth
+ 12 more
Also worked at Wellcome Trust10
Yusuf SherwaniCo-Founder and CEO at Pelago; a Londoner living in New York CityMohadeseh AbdullahiPartner at Giant Ventures Global LlpCharles SpicerNon-Executive Chair at EMV CapitalAlex GwytherInvestment Director at Mercia VenturesFreddie DearPrincipal at Monograph Capital PartnersSarah HardyDirector, Head of New Investments at Archangels
+ 4 more
